Im

Immunai

New York NYFounded 2018150 employees
Private CapbiotechPrivateOncology
Platform: Immune Map AI
Market Cap
N/A
All Drugs
3
Clinical Trials
6
Failed / Terminated
3
FDA Approved
0
Drug Pipeline (3 programs)
Drug NameCodePhaseTrialsModalityTargetMOAIndications
RilucapivasertibIMM-7670Phase 2/32VaccineGLP-1RCFTRmodAML
IMM-5834IMM-5834Phase 22DegraderFGFRKIF18AiALSADPKD
IMM-2921IMM-2921Phase 1/22Gene EditingJAK2MDM2iFTD
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (7)
2025-04-22
Rilucapivasertib Ph3 Readout
AML
Past
2026-05-18
IMM-5834 Enrollment Complete
ADPKD
Enrollment Complete
2027-03-17
IMM-2921 Ph2 Data
FTD
Ph2 Data
2028-04-12
IMM-5834 Ph2 Data
ALS
Ph2 Data
2029-02-03
Rilucapivasertib Ph3 Readout
AML
Ph3 Readout
2029-02-13
IMM-2921 Ph2 Data
FTD
Ph2 Data
2029-06-21
IMM-5834 Ph2 Data
ALS
Ph2 Data